Researchers from India have concluded that a drug could prevent infection with the new coronavirus after testing the drug on health care workers who came into contact with COVID-19 patients. The drug, called ivermectin, appeared in previous studies and has been shown in laboratory tests to be effective in treating new crowns. The researchers say iverin can reduce the risk of new coronavirus transmission, but there are several limitations that may influence the conclusions. More research is needed to prove that the drug can prevent or delay infection.
Scientists from the Bubbaneswar branch of the All India Institute of Medical Sciences (AIIMS) conducted in vitro trials with Yvonne and found that the drug was effective in blocking SARS-CoV-2. They published their findings in early April and noted the need to study actual patients to determine whether the drug is really effective. Yvonne is already a worldwide approved drug that can treat a variety of diseases caused by various pathogens, including head lice, scabies and various worms. The drug has been used in other infectious diseases, including HIV, dengue and Zika.
The researchers conducted a study between September 20 and October 19 and concluded that taking two doses of iveythroid as a precautionary measure could reduce COVID-19 infections by 73 percent, raising questions.
Doctors selected 372 health care workers for the study, half of whom tested positive for COVID-19. They divided the patients into different groups, each taking different preventive measures, including single doses of ivelucosin (77 negative, 38 positive), vitamin C (38 negative, 29 positive), three-day interval between two doses of iveythromycin (94 participants, but 26 people did not adhere to the two-dose program); and hydroxycodone (12 negative, 6 positive). It is not clear why hydroxychloroquine was included, and various studies to date have shown that the drug is ineffective in blocking or treating COVID-19.
The scientists concluded that iverin reduced the risk of transmission, while vitamin C and hydroxychloroquine had no effect. “Earlier, at least 20 to 25 (medical workers) were infected with the virus every day,” said Gtanjali Batmanabane, director of AIIMS. “By the time they started taking Yvonne, the number of infections had dropped to one or two a day.” But the researchers say a single dose of yvonne does not reduce infection rates.
At first glance, the results may seem promising, but there are still some problems. This is not a randomized placebo-controlled double-blind study, nor is it a standard for clinical trials, but an observational trial. Randomized trials comparing ivecytosin with standard care can better determine whether the drug has a practical preventive effect and is effective for COVID-19 treatment. After all, some of the patients treated with the drug in this trial have been infected with the new coronavirus. The study has not yet been reviewed, and the preprinted form can be seen on this link.